{
    "url_original": "https://www.wsj.com/articles/big-pharma-success-government-failure-covid-pills-merck-molnupiravir-pfizer-paxlovid-ridgeback-11640295905?mod=opinion_major_pos2",
    "url": "big-pharma-success-government-failure-covid-pills-merck-molnupiravir-pfizer-paxlovid-ridgeback-11640295905",
    "title": "Big Pharma Success, Government Failure",
    "sub_head": "The U.S. ordered too few courses of the new and promising Covid pills.",
    "category_1": "Opinion",
    "category_2": "Review & Outlook",
    "time": "2021-12-23 18:52:00",
    "body": "First some good news to brighten the holidays: The Food and Drug Administration has approved two oral antiviral drugs for Covid-19. Now the bad news: They will be in short supply this winter.<br />On Thursday the FDA authorized Merck and Ridgeback Biotherapeutics’ Molnupiravir for adults at high risk of severe illness following its approval of  Pfizer ’s  Paxlovid. Both will be available by prescription with proof of a positive Covid test and should be taken within five days of symptom onset."
}